## \*ImmunoReagents,Inc.

840 Main Campus Drive Suite 3520 Raleigh, NC 27606

## **Product Specifications**

Product:	Goat anti-Human IgG Fc, F(ab)'2 Fragment - Affinity Pure
Description:	Goat anti-Human IgG Fc, F(ab)'2 Fragment - Affinity Pure, FITC Conjugate
Part Number:	GtxHu-004-GFITC
Concentration:	1.50 mg/ml (E 1% at 280 nm = 13.0)
Amount:	0.5 mg
Conjugate:	Fluorescein-5-isothiocyanate (FITC) Amax = 494 nm; Emax = 518 nm
Form:	Clear, fluorescent yellow liquid
Purification:	Affinity purified using solid phase Human IgG
Purity:	> 90% based on SDS-PAGE Small amounts of intact IgG may be present.
Host:	Goat
Immunogen:	Purified Human IgG, Fc fragment
Buffer:	10 mM Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2, 1 % (w/v) BSA,
	Protease/IgG free
Preservative:	0.05% (w/v) Sodium Azide
Storage:	2-8 °C
Shelf Life:	1 year from date of receipt. Prepare working dilution prior to use and then
	discard.
Specificity:	Based on IEP, this antibody reacts with:
	<ul> <li>heavy (γ) chains on human IgG</li> </ul>
Cross Reactivity:	Based on IEP, no reactivity is observed to:
	<ul> <li>non-immunoglobulin human serum immunoglobulins</li> <li>li hi hi human immunoglobulins</li> </ul>
	<ul> <li>light chains on all human immunoglobulins</li> </ul>
Country of Origin:	Goat serum was obtained from healthy animals of US origin and under the care of a registered veterinarian.
Applications:	This conjugate is suitable for immunomicroscopy and flow cytometry. The optimal working dilution should be determined by the investigator. Suggested starting dilution(s):
	• 1:20 - 1:2,000 for most applications
Disclaimer:	For in vitro Laboratory Use Only. Not intended for diagnostic or therapeutic use.
	Not for human or animal consumption. Suggested applications of our products are
	not recommendations to use our products in violation of any patent or as a license
	under any patent of ImmunoReagents, Inc.
Phone: 919-831-2240	Fax: 919-831-2240 email: info@immunoreagents.com

Product may not be resold or modified for resale without prior written approval of ImmunoReagents, Inc.